Sophia Genetics launched Sophia DDM Digital Twins, an AI‑driven research module that creates computational patient replicas using multimodal clinical, imaging and genomic data to simulate treatment responses and disease trajectories; the product is research‑use only but positioned as a route to improve trial matching and translational research. The announcement was timed with ESMO and company statements highlighted networked de‑identified datasets powering the models. In parallel, Verily released a free consumer health app that aggregates medical records, tracks behaviors and provides AI‑powered preventive recommendations, including an assistant to contextualize user data. The app aims to broaden access to personalized preventive insights and to collect longitudinal data streams. Both launches underscore expanding commercialization of patient‑centric AI tools across research and consumer domains, raising near‑term questions about validation, data governance, and clinical integration pathways.